Xia Sheng1, Yuan Ji2, Guo-Ping Ren3, Chang-Li Lu4, Jing-Ping Yun5, Li-Hong Chen6, Bin Meng7, Li-Juan Qu8, Guang-Jie Duan9, Qing Sun10, Xin-Qing Ye11, Shan-Shan Li12, Jing Yang13, Bing Liao14, Zhan-Bo Wang15, Jian-Hua Zhou16, Yu Sun17, Xue-Shan Qiu18, Lei Wang19, Zeng-Shan Li20, Jun Chen21, Chun-Yan Xia22, Song He23, Chuan-Ying Li24, En-Wei Xu25, Jing-Shu Geng26, Chao Pan27, Dong Kuang28, Rong Qin29, Hong-Wei Guan30, Zhan-Dong Wang31, Li-Xing Li32, Xi Zhang32, Han Wang1, Qian Zhao1, Bo Wei32, Wu-Jian Zhang32, Shao-Ping Ling33, Xiang Du34, Wen-Ming Cong35. 1. Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China. 2. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. 3. Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 4. Department of Pathology, West China Hospital of Sichuan University, Chengdu, China. 5. Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China. 6. Department of Pathology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. 7. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 8. Department of Pathology, The 900Th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. 9. Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Chongqing, China. 10. Department of Pathology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China. 11. Department of Pathology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 12. Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 13. Department of Pathology, Guangzhou First People's Hospital, Guangzhou, China. 14. Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. 15. Department of Pathology, The General Hospital of the People's Liberation Army, Beijing, China. 16. Department of Pathology, Xiangya Hospital, Central South University, Changsha, China. 17. Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China. 18. Department of Pathology, The First Hospital of China Medical University, Shenyang, China. 19. Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Rd, Shanghai, 200032, China. 20. Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xian, China. 21. Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China. 22. Department of Pathology, Changzheng Hospital, Shanghai, China. 23. Department of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, China. 24. Department of Pathology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China. 25. Department of Pathology, Shanxi Cancer Hospital, Taiyuan, China. 26. Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China. 27. Department of Pathology, Zhongshan Hospital, Xiamen University, Xiamen, China. 28. Institute of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. 29. Department of Pathology, The Second Hospital of Anhui Medical University, Hefei, China. 30. Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. 31. Department of Pathology, Xuzhou Cancer Hospital, Xuzhou, China. 32. Genome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China. 33. Genome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China. frank.ling@genowis.com. 34. Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Rd, Shanghai, 200032, China. dx2008cn@163.com. 35. Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China. wmcong@smmu.edu.cn.
Abstract
BACKGROUND AND AIMS: Microvascular invasion (MVI) is a key pathological factor that severely affects the postoperative prognosis of patients with hepatocellular carcinoma (HCC). However, no MVI classification schemes based on standardized gross sampling protocols of HCC are available at present. METHODS: 119 HCC specimens were sampled at multiple sites (3-, 7-, and 13 points) for the optimum MVI detection rate. 16,144 resected HCCs were graded as M0, M1 or M2 by adopting three-tiered MVI grading (MVI-TTG) scheme based on the seven-point sampling protocol (SPSP). Survival analyses were performed on 2573 patients to explore the advantages of MVI-TTG. RESULTS: The MVI detection rate determined by SPSP was significantly higher than that determined by the 3-point sampling method (34.5% vs. 47.1%, p = 0.048), but was similar to that determined by the 13-point sampling method (47.1% vs. 51.3%, p = 0.517). Among 16,144 resected HCCs, the proportions of M0, M1 and M2 specimens according to SPSP were 53.4%, 26.2% and 20.4%, respectively. Postoperative survival analysis in 2573 HCC patients showed that the 3-year recurrence rates in M0, M1 and M2 MVI groups were 62.5%, 71.6% and 86.1%, respectively (p < 0.001), and the corresponding 3-year overall survival (OS) rates were 94.1%, 87.5% and 67.0%, respectively (p < 0.001). M1 grade was associated with early recurrence, while M2 grade was associated with both early and late recurrence. MVI-TTG had a larger area under the curve and net benefit rate than the two-tiered MVI grading scheme for predicting time to recurrence and OS. CONCLUSIONS: SPSP is a practical method to balance the efficacy of sampling numbers and MVI detection rates. MVI-TTG based on SPSP is a better prognostic predictor than the two-tiered MVI scheme. The combined use of SPSP and MVI-TTG is recommended for the routine pathological diagnosis of HCC.
BACKGROUND AND AIMS: Microvascular invasion (MVI) is a key pathological factor that severely affects the postoperative prognosis of patients with hepatocellular carcinoma (HCC). However, no MVI classification schemes based on standardized gross sampling protocols of HCC are available at present. METHODS: 119 HCC specimens were sampled at multiple sites (3-, 7-, and 13 points) for the optimum MVI detection rate. 16,144 resected HCCs were graded as M0, M1 or M2 by adopting three-tiered MVI grading (MVI-TTG) scheme based on the seven-point sampling protocol (SPSP). Survival analyses were performed on 2573 patients to explore the advantages of MVI-TTG. RESULTS: The MVI detection rate determined by SPSP was significantly higher than that determined by the 3-point sampling method (34.5% vs. 47.1%, p = 0.048), but was similar to that determined by the 13-point sampling method (47.1% vs. 51.3%, p = 0.517). Among 16,144 resected HCCs, the proportions of M0, M1 and M2 specimens according to SPSP were 53.4%, 26.2% and 20.4%, respectively. Postoperative survival analysis in 2573 HCC patients showed that the 3-year recurrence rates in M0, M1 and M2 MVI groups were 62.5%, 71.6% and 86.1%, respectively (p < 0.001), and the corresponding 3-year overall survival (OS) rates were 94.1%, 87.5% and 67.0%, respectively (p < 0.001). M1 grade was associated with early recurrence, while M2 grade was associated with both early and late recurrence. MVI-TTG had a larger area under the curve and net benefit rate than the two-tiered MVI grading scheme for predicting time to recurrence and OS. CONCLUSIONS:SPSP is a practical method to balance the efficacy of sampling numbers and MVI detection rates. MVI-TTG based on SPSP is a better prognostic predictor than the two-tiered MVI scheme. The combined use of SPSP and MVI-TTG is recommended for the routine pathological diagnosis of HCC.
Authors: Anthony W H Chan; Jianhong Zhong; Sarah Berhane; Hidenori Toyoda; Alessandro Cucchetti; KeQing Shi; Toshifumi Tada; Charing C N Chong; Bang-De Xiang; Le-Qun Li; Paul B S Lai; Vincenzo Mazzaferro; Marta García-Fiñana; Masatoshi Kudo; Takashi Kumada; Sasan Roayaie; Philip J Johnson Journal: J Hepatol Date: 2018-09-18 Impact factor: 25.083
Authors: Farhad Islami; Kimberly D Miller; Rebecca L Siegel; Stacey A Fedewa; Elizabeth M Ward; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-06-06 Impact factor: 508.702